Mary J Borses, MD
Cardiovascular Disease (Cardiology) · Petaluma
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 34 years
- Uniformed Services Uhs Fe Hebert School of Med, 1992
Offices
2 locations · Providence Medical Foundation · Sutter Bay Medical Foundation
Looking this up.
Hospitals listed: Petaluma Valley Hospital · Providence Santa Rosa Memorial Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Borses’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G79195 · Current
Licensed to practise in California · since 2014 · expires 2028-01-31 · Uniformed Services University of the Health Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas M4717Physician License · since 2006 · expires 2015-08-31Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Petaluma Valley HospitalPetaluma, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
See every measure and the patient survey for Petaluma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.23 to 2.39) · 147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.44 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 57 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 533 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,427 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,398 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.65) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 202 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.61 (0 to 18.36) · 49 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.16 (0.85 to 9.47) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.41) · 1,184 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.1 · 26 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.308 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3 · 143 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 17.8) · 364 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 138 cases | No different | Jan 2024 – Dec 2024 |
What patients said (246 patients answered, 23% of those asked)
| Cleanliness | 5 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 85% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$348,919
Medicare paid this office $348,919 for 1,054 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 580 | $163,945 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 360 | $64,303 | $171 |
| Return visit (30+ min) | 297 | $39,469 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 99 | $13,196 | $107 |
| New patient visit (60+ min) | 72 | $13,077 | $182 |
See all 24 services
| Long return visit (40+ min) | 580 | $163,945 | $144 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 360 | $64,303 | $171 |
| Return visit (30+ min) | 297 | $39,469 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 99 | $13,196 | $107 |
| New patient visit (60+ min) | 72 | $13,077 | $182 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 451 | $6,045 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $5,614 | $55 |
| Programming of dual lead pacemaker system | 43 | $4,541 | $65 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $3,817 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 62 | $3,591 | $22 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 19 | $3,011 | $53 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $2,983 | $107 |
| Telephone medical discussion with physician, 11-20 minutes | 25 | $2,127 | $73 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 89 | $2,018 | $20 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 77 | $1,862 | $19 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,841 | $142 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 251 | $1,700 | $6 |
| Blood test, clotting time | 33 | $1,226 | $4 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 15 | $1,192 | $28 |
| Heart rhythm recording of continous external ekg over 8-15 days | 82 | $875 | $10 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 62 | $766 | $10 |
| Anticoagulant management of patient taking warfarin | 22 | $655 | $9 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 31 | $183 | $6 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 12 | $125 | $10 |
Who their Medicare patients are
1,054 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 22% · Women 57% · Also on Medicaid 28% · Health risk score 1.65. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 49% · Atrial fibrillation 37% · Diabetes 32% · Heart failure 31% · Chronic kidney disease 30% · COPD 23% · Depression 23% · Cancer 17% · Stroke 14% · Dementia 12%.
The office billed $1,459,574, Medicare allowed $462,682 and paid $348,919; for 4,535 services of 55 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,054 | 4,535 | 77 | 1.65 | $1,459,574 | $348,919 |
| 2023 | 912 | 4,006 | 77 | 1.63 | $950,238 | $264,758 |
| 2022 | 1,022 | 3,316 | 77 | 1.68 | $806,654 | $229,749 |
| 2021 | 712 | 2,109 | 76 | 1.84 | $440,244 | $171,119 |
| 2020 | 224 | 1,526 | 78 | 2.49 | $259,638 | $103,039 |
| 2019 | 234 | 1,783 | 79 | 2.51 | $284,769 | $114,045 |
| 2018 | 1,179 | 2,886 | 77 | 1.56 | $367,957 | $109,264 |
| 2017 | 2,001 | 4,660 | 77 | 1.54 | $562,136 | $159,125 |
| 2016 | 2,041 | 4,786 | 78 | 1.57 | $524,163 | $153,506 |
| 2015 | 1,145 | 2,821 | 78 | 1.53 | $305,077 | $98,969 |
| 2014 | 122 | 355 | 73 | 1.67 | $74,837 | $17,554 |
| 2013 | 411 | 1,304 | 73 | 1.75 | $272,674 | $64,741 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Long return visit (40+ min) | 409 | $133,808 | $145 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 183 | $32,280 | $172 |
| Return visit (30+ min) | 191 | $24,987 | $98 |
| Telephone medical discussion with physician, 21-30 minutes | 94 | $12,624 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 189 | $10,507 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 352 | $4,866 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $4,734 | $19 |
| New patient visit (60+ min) | 21 | $3,477 | $166 |
| Programming of dual lead pacemaker system | 33 | $3,340 | $55 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 47 | $3,152 | $24 |
| Telephone medical discussion with physician, 11-20 minutes | 37 | $3,132 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 372 | $2,909 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,631 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,374 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $1,999 | $143 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 64 | $1,356 | $21 |
| Telephone medical discussion with physician, 5-10 minutes | 23 | $1,283 | $44 |
| Blood test, clotting time | 29 | $1,184 | $4 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $1,086 | $27 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 49 | $1,062 | $19 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 14 | $917 | $20 |
| Short return visit (20+ min) | 13 | $861 | $66 |
| Heart rhythm recording of continous external ekg over 8-15 days | 59 | $645 | $11 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 43 | $472 | $10 |
2022: 22 services
| Long return visit (40+ min) | 316 | $80,455 | $149 |
| Return visit (30+ min) | 245 | $54,040 | $107 |
| New patient visit (60+ min) | 115 | $19,657 | $171 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 91 | $16,142 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 223 | $13,245 | $59 |
| Telephone medical discussion with physician, 21-30 minutes | 62 | $7,226 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,410 | $163 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 475 | $3,726 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 237 | $3,471 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $3,143 | $20 |
| Programming of dual lead pacemaker system | 22 | $2,108 | $68 |
| Short return visit (20+ min) | 23 | $1,855 | $71 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 55 | $1,379 | $22 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,257 | $79 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,131 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,117 | $59 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 27 | $1,092 | $25 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 47 | $969 | $19 |
| Telephone medical discussion with physician, 5-10 minutes | 18 | $884 | $49 |
| Blood test, clotting time | 28 | $705 | $4 |
| Heart rhythm recording of continous external ekg over 8-15 days | 54 | $666 | $12 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 42 | $491 | $11 |
2021: 21 services
| Long return visit (40+ min) | 131 | $31,051 | $158 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 124 | $21,870 | $172 |
| New patient visit (60+ min) | 88 | $16,629 | $189 |
| New patient visit (45+ min) | 114 | $15,700 | $138 |
| Return visit (30+ min) | 104 | $14,930 | $113 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 212 | $12,771 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $11,315 | $169 |
| Short return visit (20+ min) | 97 | $11,250 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $4,732 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $4,547 | $87 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,376 | $95 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $2,325 | $75 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 155 | $2,143 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 202 | $1,589 | $7 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,487 | $114 |
| Telephone medical discussion with physician, 5-10 minutes | 27 | $1,094 | $32 |
| New patient visit (30+ min) | 11 | $979 | $89 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $574 | $13 |
| Heart rhythm recording of continous external ekg over 8-15 days | 32 | $535 | $14 |
| Ultrasound of heart, follow-up | 12 | $282 | $20 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $38 | $3 |
2020: 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 137 | $25,427 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $12,377 | $179 |
| Return visit (30+ min) | 53 | $10,197 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $8,674 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 30 | $6,624 | $207 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 11 | $5,461 | $496 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | $5,264 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 57 | $4,602 | $66 |
| Short return visit (20+ min) | 47 | $4,539 | $61 |
| Long return visit (40+ min) | 24 | $4,394 | $129 |
| Telephone medical discussion with physician, 11-20 minutes | 32 | $3,835 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,598 | $107 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 11 | $1,065 | $97 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 34 | $741 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 13 | $151 | $12 |
| Insertion of needle into vein for collection of blood sample | 12 | $36 | $3 |
2019: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 134 | $32,134 | $66 |
| Return visit (30+ min) | 73 | $12,915 | $102 |
| Short return visit (20+ min) | 76 | $12,073 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $11,350 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $6,518 | $123 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 28 | $6,268 | $209 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $4,873 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 53 | $3,900 | $66 |
| Initial hospital observation care per day, typically 70 minutes | 11 | $1,815 | $165 |
| Long return visit (40+ min) | 11 | $1,785 | $137 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 12 | $770 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $286 | $14 |
| Insertion of needle into vein for collection of blood sample | 14 | $44 | $3 |
2018: 24 services
| Short return visit (20+ min) | 235 | $21,952 | $57 |
| Return visit (30+ min) | 154 | $18,003 | $84 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 159 | $9,404 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 147 | $7,893 | $54 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $6,565 | $164 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $6,228 | $62 |
| Long return visit (40+ min) | 42 | $5,966 | $117 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 65 | $5,522 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,282 | $113 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 35 | $2,515 | $70 |
| Blood test, clotting time | 141 | $2,195 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 79 | $2,098 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 245 | $1,848 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,719 | $82 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 97 | $1,608 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 75 | $1,314 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 65 | $1,068 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 75 | $880 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 65 | $721 | $11 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 27 | $466 | $17 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 17 | $354 | $21 |
| Ultrasound of heart, follow-up | 13 | $275 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $197 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $45 | $3 |
2017: 29 services
| Return visit (30+ min) | 218 | $29,725 | $84 |
| Short return visit (20+ min) | 225 | $19,315 | $56 |
| Long return visit (40+ min) | 94 | $14,843 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $12,730 | $163 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 224 | $11,333 | $50 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 234 | $11,008 | $47 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 866 | $7,320 | $7 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 113 | $6,916 | $61 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 68 | $4,876 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $4,837 | $58 |
| Blood test, clotting time | 251 | $4,415 | $5 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $3,812 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $3,656 | $111 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 118 | $3,431 | $14 |
| New patient visit (60+ min) | 16 | $2,696 | $169 |
| New patient visit (45+ min) | 21 | $2,628 | $125 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 115 | $1,956 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 113 | $1,828 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 115 | $1,314 | $11 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 61 | $1,300 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 61 | $1,109 | $18 |
| External shock to heart to regulate heart beat | 12 | $1,086 | $90 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 61 | $742 | $12 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 12 | $702 | $54 |
| Ultrasound of heart, follow-up | 19 | $464 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 13 | $255 | $20 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 11 | $229 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 15 | $226 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $45 | $2 |
2016: 30 services
| Return visit (30+ min) | 192 | $30,393 | $86 |
| Short return visit (20+ min) | 204 | $20,966 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 269 | $13,349 | $50 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 190 | $10,010 | $52 |
| Long return visit (40+ min) | 51 | $7,721 | $115 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 913 | $7,537 | $7 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $7,055 | $164 |
| New patient visit (45+ min) | 46 | $6,192 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 54 | $6,074 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $5,144 | $58 |
| Blood test, clotting time | 306 | $5,103 | $5 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 69 | $5,025 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 158 | $4,947 | $15 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 81 | $4,903 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,359 | $84 |
| New patient visit (60+ min) | 12 | $1,802 | $150 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 100 | $1,766 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 101 | $1,641 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 69 | $1,275 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 100 | $1,151 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 52 | $1,088 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 69 | $831 | $12 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 11 | $644 | $59 |
| Ultrasound of heart, follow-up | 17 | $359 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 16 | $341 | $21 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 11 | $239 | $22 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $196 | $15 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $181 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 15 | $39 | $3 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $32 | $3 |
2015: 22 services
| Return visit (30+ min) | 151 | $22,521 | $87 |
| Short return visit (20+ min) | 140 | $14,890 | $59 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $14,024 | $52 |
| New patient visit (45+ min) | 80 | $10,226 | $128 |
| Long return visit (40+ min) | 31 | $4,074 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,797 | $165 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 407 | $3,498 | $7 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,336 | $111 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 112 | $3,203 | $16 |
| Blood test, clotting time | 223 | $3,097 | $5 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $2,594 | $59 |
| New patient visit (60+ min) | 14 | $2,092 | $149 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 128 | $2,000 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 88 | $1,533 | $17 |
| Programming of dual lead pacemaker system | 21 | $1,050 | $44 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 88 | $1,011 | $11 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 13 | $661 | $51 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 27 | $596 | $22 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 21 | $458 | $22 |
| Ultrasound of heart, follow-up | 11 | $275 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $151 | $14 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 12 | $31 | $3 |
2014: 6 services
| Short return visit (20+ min) | 72 | $7,096 | $49 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 21 | $3,245 | $155 |
| Return visit (30+ min) | 20 | $1,999 | $71 |
| New patient visit (45+ min) | 13 | $1,403 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,182 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 37 | $478 | $11 |
2013: 16 services
| Short return visit (20+ min) | 126 | $16,119 | $53 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $10,728 | $114 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 158 | $7,635 | $47 |
| Return visit (30+ min) | 46 | $5,474 | $75 |
| New patient visit (45+ min) | 47 | $5,424 | $115 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 19 | $3,334 | $175 |
| New patient visit (60+ min) | 12 | $1,822 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,736 | $145 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 95 | $1,479 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 86 | $1,412 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,134 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 86 | $940 | $11 |
| Blood test, clotting time | 18 | $632 | $5 |
| Electrocardiogram (ecg) 2-day continuous | 24 | $462 | $18 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 23 | $450 | $19 |
| Short return visit | 12 | $431 | $29 |
Medicaid work
$33,067 in 2024
Medicaid paid $33,067 for 830 billed services this clinician did in 2024, up to 162 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 126 | $13,885 |
| Long return visit (40+ min) | 255 | $11,469 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 325 | $4,723 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 111 | $2,746 |
| Return visit (30+ min) | 13 | $244 |
| 2024 | 830 | 5 | 162 | $33,067 |
| 2023 | 729 | 3 | 106 | $28,655 |
| 2022 | 674 | 6 | 96 | $26,334 |
| 2021 | 412 | 3 | 57 | $21,016 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 120 | $12,277 |
| Long return visit (40+ min) | 280 | $10,280 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 329 | $6,097 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 136 | $10,880 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 322 | $5,952 |
| Long return visit (40+ min) | 111 | $5,384 |
| Return visit (30+ min) | 55 | $1,831 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 33 | $1,197 |
| New patient visit (60+ min) | 17 | $1,090 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 145 | $15,408 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 224 | $3,473 |
| Long return visit (40+ min) | 43 | $2,135 |
Drugs they prescribed that Part D paid
$803,486
Pharmacies billed $803,486 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,852) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,289 generic and 563 brand-name prescriptions · $803,486 in drug cost · 19 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 243 | $350,569 | $1,443 |
| Jardiance | 84 | $118,306 | $1,408 |
| Xarelto | 67 | $105,797 | $1,579 |
| Entresto | 43 | $71,255 | $1,657 |
| Repatha Sureclick | 46 | $66,692 | $1,450 |
See all 40 drugs
| Eliquis | 243 | $350,569 | $1,443 |
| Jardiance | 84 | $118,306 | $1,408 |
| Xarelto | 67 | $105,797 | $1,579 |
| Entresto | 43 | $71,255 | $1,657 |
| Repatha Sureclick | 46 | $66,692 | $1,450 |
| Atorvastatin | 570 | $6,440 | $11 |
| Metoprolol | 265 | $4,305 | $16 |
| Rosuvastatin | 145 | $2,776 | $19 |
| Ezetimibe | 83 | $2,707 | $33 |
| Digoxin | 83 | $2,365 | $28 |
| Flecainide Acetate | 52 | $2,276 | $44 |
| Losartan | 190 | $2,197 | $12 |
| Carvedilol | 161 | $2,059 | $13 |
| Spironolactone | 113 | $1,790 | $16 |
| Potassium Chloride | 62 | $1,732 | $28 |
| Amlodipine Besylate | 245 | $1,668 | $7 |
| Lisinopril | 182 | $1,541 | $8 |
| Metoprolol | 191 | $1,499 | $8 |
| Omega-3 Acid Ethyl Esters | 14 | $1,336 | $95 |
| Furosemide | 165 | $1,273 | $8 |
| Warfarin | 71 | $1,019 | $14 |
| Diltiazem 24hr Er (Cd) | 27 | $1,009 | $37 |
| Hydralazine | 48 | $946 | $20 |
| Valsartan | 27 | $860 | $32 |
| Dilt-Xr | 18 | $790 | $44 |
| Sotalol | 19 | $606 | $32 |
| Triamterene-Hydrochlorothiazid | 34 | $516 | $15 |
| Clopidogrel | 42 | $495 | $12 |
| Diltiazem 24hr Er | 18 | $434 | $24 |
| Isosorbide Mononitrate Er | 19 | $378 | $20 |
| Simvastatin | 34 | $377 | $11 |
| Amiodarone | 30 | $376 | $13 |
| Hydrochlorothiazide | 29 | $323 | $11 |
| Atenolol | 38 | $306 | $8 |
| Pravastatin | 31 | $257 | $8 |
| Nitroglycerin | 16 | $254 | $16 |
| Labetalol | 11 | $252 | $23 |
| Benazepril | 27 | $234 | $9 |
| Levothyroxine | 12 | $125 | $10 |
| Amoxicillin | 18 | $21 | $1 |
Year by year
| 2024 | 3,852 | 543 | 0% (0) | 15% | $803,486 |
| 2023 | 3,341 | 489 | None | 15% | $688,166 |
| 2022 | 1,811 | 341 | 0% (0) | 15% | $323,409 |
| 2021 | 839 | 179 | 0% (0) | 15% | $117,726 |
| 2020 | 655 | 79 | 0% (0) | 18% | $99,339 |
| 2019 | 668 | 162 | None | 19% | $72,764 |
| 2018 | 1,991 | 247 | 0% (0) | 15% | $189,634 |
| 2017 | 1,891 | 234 | 0% (0) | 23% | $189,531 |
| 2016 | 1,519 | 204 | 0% (0) | 21% | $138,388 |
| 2015 | 709 | 148 | 0% (0) | 23% | $49,784 |
| 2014 | 627 | 94 | 0% (0) | 22% | $36,908 |
| 2013 | 775 | 117 | None | None | $42,990 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 40 drugs
| Eliquis | 180 | $258,516 | $1,436 |
| Xarelto | 78 | $111,387 | $1,428 |
| Entresto | 39 | $69,915 | $1,793 |
| Jardiance | 43 | $68,426 | $1,591 |
| Repatha Sureclick | 56 | $57,252 | $1,022 |
| Atorvastatin | 426 | $7,870 | $18 |
| Livalo | 13 | $6,922 | $532 |
| Metoprolol | 220 | $5,335 | $24 |
| Ezetimibe | 67 | $3,879 | $58 |
| Rosuvastatin | 125 | $3,493 | $28 |
| Losartan | 154 | $3,365 | $22 |
| Carvedilol | 160 | $2,871 | $18 |
| Digoxin | 89 | $2,790 | $31 |
| Potassium Chloride | 77 | $2,645 | $34 |
| Flecainide Acetate | 37 | $2,555 | $69 |
| Spironolactone | 118 | $2,409 | $20 |
| Lisinopril | 161 | $2,081 | $13 |
| Amlodipine Besylate | 186 | $1,967 | $11 |
| Diltiazem 24hr Er (Cd) | 49 | $1,652 | $34 |
| Metoprolol | 158 | $1,563 | $10 |
| Furosemide | 141 | $1,224 | $9 |
| Hydralazine | 50 | $1,210 | $24 |
| Warfarin | 63 | $1,183 | $19 |
| Valsartan | 27 | $1,136 | $42 |
| Simvastatin | 55 | $952 | $17 |
| Sotalol | 31 | $790 | $25 |
| Diltiazem 24hr Er | 20 | $722 | $36 |
| Isosorbide Mononitrate Er | 23 | $680 | $30 |
| Diltiazem 24hr Er (Xr) | 11 | $638 | $58 |
| Levothyroxine | 24 | $611 | $25 |
| Amiodarone | 19 | $536 | $28 |
| Nitroglycerin | 11 | $501 | $46 |
| Clopidogrel | 37 | $440 | $12 |
| Benazepril | 27 | $419 | $16 |
| Triamterene-Hydrochlorothiazid | 39 | $409 | $10 |
| Pravastatin | 21 | $390 | $19 |
| Clonidine | 15 | $341 | $23 |
| Pantoprazole | 12 | $297 | $25 |
| Hydrochlorothiazide | 34 | $252 | $7 |
| Atenolol | 25 | $215 | $9 |
2022: 27 drugs
| Eliquis | 80 | $115,112 | $1,439 |
| Xarelto | 40 | $47,400 | $1,185 |
| Entresto | 35 | $46,260 | $1,322 |
| Repatha Sureclick | 30 | $22,588 | $753 |
| Atorvastatin | 243 | $3,784 | $16 |
| Ezetimibe | 44 | $2,495 | $57 |
| Rosuvastatin | 55 | $2,456 | $45 |
| Metoprolol | 99 | $2,241 | $23 |
| Carvedilol | 116 | $2,127 | $18 |
| Flecainide Acetate | 22 | $1,813 | $82 |
| Potassium Chloride | 35 | $1,588 | $45 |
| Digoxin | 32 | $1,423 | $44 |
| Amlodipine Besylate | 141 | $1,312 | $9 |
| Diltiazem 24hr Er (Cd) | 19 | $1,299 | $68 |
| Metoprolol | 126 | $1,208 | $10 |
| Lisinopril | 94 | $1,033 | $11 |
| Spironolactone | 48 | $952 | $20 |
| Losartan | 67 | $902 | $13 |
| Warfarin | 38 | $841 | $22 |
| Furosemide | 74 | $621 | $8 |
| Sotalol | 27 | $595 | $22 |
| Simvastatin | 38 | $592 | $16 |
| Pravastatin | 14 | $208 | $15 |
| Clopidogrel | 11 | $171 | $16 |
| Hydralazine | 11 | $154 | $14 |
| Hydrochlorothiazide | 15 | $147 | $10 |
| Triamterene-Hydrochlorothiazid | 13 | $105 | $8 |
2021: 19 drugs
| Eliquis | 69 | $74,050 | $1,073 |
| Ezetimibe | 33 | $1,942 | $59 |
| Digoxin | 39 | $1,600 | $41 |
| Atorvastatin | 68 | $1,303 | $19 |
| Diltiazem 24hr Er (Cd) | 12 | $1,262 | $105 |
| Metoprolol | 33 | $1,216 | $37 |
| Rosuvastatin | 16 | $1,048 | $66 |
| Carvedilol | 59 | $833 | $14 |
| Potassium Chloride | 23 | $658 | $29 |
| Metoprolol | 55 | $516 | $9 |
| Losartan | 22 | $429 | $19 |
| Lisinopril | 50 | $411 | $8 |
| Spironolactone | 26 | $398 | $15 |
| Warfarin | 13 | $358 | $28 |
| Amlodipine Besylate | 58 | $331 | $6 |
| Valsartan | 15 | $297 | $20 |
| Hydralazine | 14 | $230 | $16 |
| Furosemide | 30 | $153 | $5 |
| Simvastatin | 16 | $149 | $9 |
2020: 18 drugs
| Eliquis | 54 | $60,640 | $1,123 |
| Digoxin | 40 | $1,756 | $44 |
| Ezetimibe | 12 | $1,575 | $131 |
| Metoprolol | 35 | $1,546 | $44 |
| Isosorbide Dinitrate | 11 | $1,190 | $108 |
| Potassium Chloride | 27 | $850 | $31 |
| Atorvastatin | 31 | $706 | $23 |
| Carvedilol | 43 | $598 | $14 |
| Spironolactone | 15 | $420 | $28 |
| Levothyroxine | 11 | $332 | $30 |
| Amlodipine Besylate | 40 | $315 | $8 |
| Hydralazine | 11 | $308 | $28 |
| Pantoprazole | 16 | $280 | $17 |
| Losartan | 23 | $246 | $11 |
| Furosemide | 33 | $145 | $4 |
| Metoprolol | 22 | $118 | $5 |
| Atenolol | 13 | $100 | $8 |
| Lisinopril | 19 | $87 | $5 |
2019: 17 drugs
| Eliquis | 46 | $36,168 | $786 |
| Xarelto | 18 | $11,221 | $623 |
| Digoxin | 26 | $1,481 | $57 |
| Metoprolol | 29 | $1,279 | $44 |
| Atorvastatin | 28 | $931 | $33 |
| Carvedilol | 64 | $713 | $11 |
| Bumetanide | 12 | $653 | $54 |
| Potassium Chloride | 23 | $537 | $23 |
| Losartan | 22 | $520 | $24 |
| Warfarin | 13 | $512 | $39 |
| Amlodipine Besylate | 43 | $479 | $11 |
| Metoprolol | 39 | $272 | $7 |
| Spironolactone | 11 | $272 | $25 |
| Clopidogrel | 12 | $261 | $22 |
| Atenolol | 17 | $175 | $10 |
| Furosemide | 28 | $171 | $6 |
| Lisinopril | 17 | $119 | $7 |
2018: 35 drugs
| Xarelto | 87 | $66,471 | $764 |
| Eliquis | 58 | $48,507 | $836 |
| Pradaxa | 13 | $14,196 | $1,092 |
| Bystolic | 28 | $5,245 | $187 |
| Warfarin | 151 | $3,859 | $26 |
| Digoxin | 60 | $3,613 | $60 |
| Atorvastatin | 110 | $2,806 | $26 |
| Metoprolol | 82 | $2,664 | $32 |
| Carvedilol | 173 | $2,216 | $13 |
| Digox | 30 | $2,004 | $67 |
| Ezetimibe | 13 | $1,847 | $142 |
| Bumetanide | 26 | $1,677 | $65 |
| Metoprolol | 179 | $1,164 | $7 |
| Rosuvastatin | 19 | $1,162 | $61 |
| Amlodipine Besylate | 88 | $1,077 | $12 |
| Potassium Chloride | 37 | $1,013 | $27 |
| Diltiazem 24hr Er (Cd) | 23 | $1,007 | $44 |
| Flecainide Acetate | 16 | $854 | $53 |
| Losartan | 79 | $829 | $10 |
| Lisinopril | 100 | $787 | $8 |
| Valsartan | 12 | $681 | $57 |
| Hydralazine | 30 | $540 | $18 |
| Simvastatin | 62 | $537 | $9 |
| Pravastatin | 18 | $457 | $25 |
| Cartia Xt | 11 | $433 | $39 |
| Spironolactone | 53 | $417 | $8 |
| Furosemide | 79 | $398 | $5 |
| Levothyroxine | 20 | $386 | $19 |
| Jantoven | 21 | $385 | $18 |
| Sotalol | 15 | $365 | $24 |
| Amiodarone | 27 | $342 | $13 |
| Clopidogrel | 13 | $327 | $25 |
| Atenolol | 18 | $164 | $9 |
| Triamterene-Hydrochlorothiazid | 16 | $153 | $10 |
| Hydrochlorothiazide | 13 | $123 | $9 |
2017: 33 drugs
| Xarelto | 108 | $73,591 | $681 |
| Eliquis | 52 | $42,543 | $818 |
| Pradaxa | 13 | $9,980 | $768 |
| Bystolic | 40 | $7,602 | $190 |
| Digoxin | 66 | $5,016 | $76 |
| Metoprolol | 71 | $3,582 | $50 |
| Warfarin | 141 | $3,474 | $25 |
| Metoprolol | 174 | $2,679 | $15 |
| Digox | 32 | $1,951 | $61 |
| Atorvastatin | 89 | $1,877 | $21 |
| Potassium Chloride | 52 | $1,724 | $33 |
| Amiodarone | 34 | $1,571 | $46 |
| Bumetanide | 24 | $1,452 | $60 |
| Carvedilol | 135 | $1,383 | $10 |
| Lisinopril | 122 | $1,092 | $9 |
| Diltiazem 24hr Er | 20 | $981 | $49 |
| Amlodipine Besylate | 92 | $935 | $10 |
| Flecainide Acetate | 14 | $917 | $65 |
| Cartia Xt | 24 | $868 | $36 |
| Rosuvastatin | 11 | $790 | $72 |
| Valsartan | 15 | $753 | $50 |
| Losartan | 63 | $620 | $10 |
| Hydralazine | 21 | $514 | $24 |
| Simvastatin | 66 | $481 | $7 |
| Furosemide | 78 | $461 | $6 |
| Jantoven | 24 | $437 | $18 |
| Pravastatin | 13 | $399 | $31 |
| Isosorbide Mononitrate Er | 15 | $380 | $25 |
| Spironolactone | 28 | $315 | $11 |
| Sotalol | 21 | $266 | $13 |
| Hydrochlorothiazide | 11 | $98 | $9 |
| Triamterene-Hydrochlorothiazid | 12 | $94 | $8 |
| Atenolol | 17 | $74 | $4 |
2016: 28 drugs
| Xarelto | 92 | $50,907 | $553 |
| Eliquis | 34 | $24,491 | $720 |
| Bystolic | 19 | $4,093 | $215 |
| Digoxin | 52 | $4,071 | $78 |
| Metoprolol | 54 | $2,372 | $44 |
| Warfarin | 133 | $2,246 | $17 |
| Atorvastatin | 82 | $2,101 | $26 |
| Bumetanide | 32 | $1,984 | $62 |
| Amiodarone | 16 | $1,750 | $109 |
| Carvedilol | 102 | $1,360 | $13 |
| Metoprolol | 128 | $1,268 | $10 |
| Coumadin | 14 | $1,135 | $81 |
| Lisinopril | 112 | $941 | $8 |
| Toprol Xl | 12 | $793 | $66 |
| Flecainide Acetate | 16 | $758 | $47 |
| Digox | 15 | $754 | $50 |
| Losartan | 64 | $664 | $10 |
| Amlodipine Besylate | 62 | $635 | $10 |
| Simvastatin | 65 | $506 | $8 |
| Jantoven | 27 | $438 | $16 |
| Potassium Chloride | 16 | $431 | $27 |
| Clopidogrel | 19 | $393 | $21 |
| Isosorbide Mononitrate Er | 15 | $355 | $24 |
| Sotalol | 16 | $342 | $21 |
| Enalapril Maleate | 12 | $323 | $27 |
| Spironolactone | 13 | $169 | $13 |
| Furosemide | 22 | $115 | $5 |
| Atenolol | 13 | $93 | $7 |
2015: 16 drugs
| Xarelto | 43 | $17,422 | $405 |
| Eliquis | 14 | $7,761 | $554 |
| Metoprolol | 25 | $1,255 | $50 |
| Warfarin | 86 | $1,249 | $15 |
| Atorvastatin | 30 | $1,019 | $34 |
| Bumetanide | 16 | $744 | $46 |
| Carvedilol | 59 | $582 | $10 |
| Flecainide Acetate | 12 | $575 | $48 |
| Metoprolol | 60 | $553 | $9 |
| Lisinopril | 45 | $388 | $9 |
| Potassium Chloride | 12 | $371 | $31 |
| Simvastatin | 37 | $341 | $9 |
| Amlodipine Besylate | 43 | $333 | $8 |
| Losartan | 25 | $269 | $11 |
| Enalapril Maleate | 11 | $232 | $21 |
| Furosemide | 13 | $99 | $8 |
2014: 14 drugs
| Xarelto | 40 | $14,484 | $362 |
| Metoprolol | 19 | $1,140 | $60 |
| Carvedilol | 56 | $671 | $12 |
| Atorvastatin | 20 | $578 | $29 |
| Amlodipine Besylate | 58 | $529 | $9 |
| Metoprolol | 57 | $443 | $8 |
| Lisinopril | 46 | $382 | $8 |
| Warfarin | 31 | $306 | $10 |
| Losartan | 16 | $222 | $14 |
| Simvastatin | 13 | $205 | $16 |
| Furosemide | 23 | $192 | $8 |
| Hydrochlorothiazide | 31 | $136 | $4 |
| Jantoven | 14 | $134 | $10 |
| Spironolactone | 14 | $120 | $9 |
2013: 18 drugs
| Xarelto | 23 | $11,005 | $478 |
| Zetia | 18 | $3,494 | $194 |
| Ranexa | 12 | $2,996 | $250 |
| Metoprolol | 44 | $2,257 | $51 |
| Atorvastatin | 34 | $1,453 | $43 |
| Clopidogrel | 24 | $890 | $37 |
| Metoprolol | 76 | $720 | $9 |
| Losartan | 17 | $634 | $37 |
| Carvedilol | 41 | $631 | $15 |
| Amlodipine Besylate | 61 | $545 | $9 |
| Warfarin | 42 | $527 | $13 |
| Amiodarone | 15 | $488 | $33 |
| Simvastatin | 35 | $443 | $13 |
| Lisinopril | 47 | $424 | $9 |
| Digox | 19 | $269 | $14 |
| Furosemide | 46 | $236 | $5 |
| Atenolol | 19 | $166 | $9 |
| Hydrochlorothiazide | 19 | $163 | $9 |
Money from drug and device companies
$801 in 2025
| 2025 | 11 | 38 | None | $801 |
| 2024 | 13 | 36 | None | $719 |
| 2023 | 10 | 29 | None | $759 |
| 2022 | 13 | 33 | None | $1,030 |
| 2021 | 12 | 18 | None | $455 |
| 2020 | 1 | 2 | None | $24 |
| 2019 | 16 | 44 | None | $2,290 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Vyndaqel | $263 | 11 payments
|
| Amgen | Repatha | $204 | 14 payments
|
| Boston Scientific | Watchman Flx | $96 | 2 payments
|
| Novartis Pharmaceuticals | Leqvio | $71 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $45 | 2 payments
|
| Esperion Therapeutics | Nexletol | $30 | 1 payment
|
See all 38 published payments
| Amgen | Meals · 2025-12-23 | Repatha | $6 |
| Pfizer | Meals · 2025-12-11 | Vyndaqel | $25 |
| Boston Scientific | Meals · 2025-12-09 | Watchman Flx | $48 |
| BridgeBio Pharma | Meals · 2025-11-25 | Attruby | $18 |
| Amgen | Meals · 2025-11-18 | Repatha | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-28 | Wainua | $18 |
| Amgen | Meals · 2025-10-22 | Repatha | $4 |
| Actelion Pharmaceuticals US | Meals · 2025-10-13 | Opsynvi | $28 |
| Amgen | Meals · 2025-09-23 | Repatha | $6 |
| Pfizer | Meals · 2025-09-16 | Eliquis | $29 |
| Amgen | Meals · 2025-09-11 | Repatha | $8 |
| Pfizer | Meals · 2025-09-10 | Vyndaqel | $14 |
| Amgen | Meals · 2025-08-25 | Repatha | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-19 | Kerendia | $22 |
| Amgen | Meals · 2025-08-14 | Repatha | $23 |
| Pfizer | Meals · 2025-07-29 | Vyndaqel | $29 |
| Amgen | Meals · 2025-06-24 | Repatha | $10 |
| Inspire Medical Systems | Meals · 2025-06-19 | Inspire | $15 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-17 | Jardiance | $15 |
| Pfizer | Meals · 2025-06-09 | Vyndaqel | $13 |
| Amgen | Meals · 2025-05-28 | Repatha | $27 |
| Pfizer | Meals · 2025-05-15 | Vyndaqel | $19 |
| Amgen | Meals · 2025-05-13 | Repatha | $19 |
| Amgen | Meals · 2025-04-29 | Repatha | $7 |
| Amgen | Meals · 2025-04-10 | Repatha | $5 |
| Pfizer | Meals · 2025-04-08 | Vyndaqel | $20 |
| Boston Scientific | Meals · 2025-04-02 | Watchman Flx | $47 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-26 | Kerendia | $23 |
| Novartis Pharmaceuticals | Meals · 2025-03-25 | Leqvio | $28 |
| Amgen | Meals · 2025-03-18 | Repatha | $5 |
| Amgen | Meals · 2025-03-13 | Repatha | $30 |
| Pfizer | Meals · 2025-03-11 | Vyndaqel | $26 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Leqvio | $22 |
| Pfizer | Meals · 2025-02-18 | Vyndaqel | $26 |
| Esperion Therapeutics | Meals · 2025-02-06 | Nexletol | $30 |
| Novartis Pharmaceuticals | Meals · 2025-01-28 | Leqvio | $21 |
| Pfizer | Meals · 2025-01-28 | Vyndaqel | $25 |
| Pfizer | Meals · 2025-01-21 | Eliquis | $39 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $719
| Amgen | Repatha | $148 | 11 payments
|
| Novartis Pharmaceuticals | Leqvio | $104 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $84 | 4 payments
|
| Pfizer | Eliquis | $57 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $55 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $52 | 3 payments
|
| Boston Scientific | Bodyguardian | $50 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $43 | 2 payments
|
| Artivion | Cryovalve Sg Pulmonary Human Heart Valve | $36 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $30 | 1 payment
|
| Recor Medical | Paradise Renal Denervation System | $25 | 1 payment
|
| Esperion Therapeutics | Nexletol | $18 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $17 | 1 payment
|
2023: $759
| Edwards Lifesciences | None | $164 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $142 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $94 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $86 | 4 payments
|
| Amgen | Repatha | $66 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $65 | 2 payments
|
| Boston Scientific | Watchman Access System | $63 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $33 | 1 payment
|
| Esperion Therapeutics | Nexletol | $26 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $20 | 1 payment
|
2022: $1,030
| Abbott Laboratories | Mitraclip | $316 | 3 payments
|
| Esperion Therapeutics | Nexlizet | $173 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $137 | 7 payments
|
| Baxter Healthcare | None | $90 | 1 payment
|
| Boston Scientific | Watchman Access System | $75 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $57 | 5 payments
|
| Amgen | Repatha | $56 | 3 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $30 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $22 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $21 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $20 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $19 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $14 | 1 payment
|
2021: $455
| Medtronic | Venaseal | $73 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $71 | 4 payments
|
| Boston Scientific | Watchman | $63 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $53 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $42 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $27 | 1 payment
|
| Esperion Therapeutics | Nexletol | $26 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $25 | 1 payment
|
| Preventice Services | Bg Mini Plus | $24 | 1 payment
|
| Merck Sharp & Dohme | None | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $16 | 1 payment
|
| Abbott Laboratories | Cardiomems Hf System | $15 | 1 payment
|
2020: $24
| Novartis Pharmaceuticals | Entresto | $24 | 2 payments
|
2019: $2,290
| Boston Scientific | Watchman | $1,695 | 11 payments
|
| Actelion Pharmaceuticals US | Uptravi | $135 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $72 | 4 payments
|
| Novartis Pharmaceuticals | Entresto | $61 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $58 | 5 payments
|
| Pfizer | Vyndaqel | $50 | 2 payments
|
| AtriCure | Atricure Synergy Ablation System | $43 | 2 payments
|
| Amgen | Corlanor | $42 | 3 payments
|
| Akcea Therapeutics | Tegsedi | $26 | 1 payment
|
| GlaxoSmithKline | Benlysta | $25 | 1 payment
|
| Amarin Pharma | Vascepa | $20 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $16 | 1 payment
|
| Aegerion Pharmaceuticals | Juxtapid | $12 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $12 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $12 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $12 | 1 payment
|
Professional record
- NPI
- 1164513297
- Licence
- CA G79195, TX M4717California G79195: Current · expires 2028-01-31Texas M4717: Canc Non-Renewal
- Trained
- Uniformed Services Uhs Fe Hebert School of Med, 1992 · 34 years ago
- Group
- Providence Medical Foundation · Sutter Bay Medical Foundation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- TX 200605802, TX 200605803, TX 200605804, TX 200605805
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 30 Garden Ct, Suite B, Monterey, CA, 93940
- NPI first listed
- 2006-09-27
- NPI last updated
- 2021-10-15
- NPI record certified
- 2021-10-15
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.